Trial reportHeart (British Cardiac Society)2007
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
Trial report in Heart (British Cardiac Society), 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.PharmacoEconomics · 2013Pooled it
- Trial
- Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk.Diabetes care · 2010Trial
- Clinical evaluation of magnetic resonance imaging in coronary heart disease: the CE-MARC study.Trials · 2009Trial
- Article
- A Review of Heterogeneity in Comparative Economic Analysis, with Specific Considerations for the Decentralized US Setting and Patient-Centered Care.PharmacoEconomics · 2025Review
- Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.PharmacoEconomics · 2023Article
- The cost-effectiveness of tailored smoking cessation interventions for people with severe mental illness: a model-based economic evaluation.EClinicalMedicine · 2023Article
- Cost-effectiveness analysis of new generation coronary CT scanners for difficult-to-image patients.The European journal of health economics : HEPAC : health economics in prevention and care · 2017Article
- Using electronic health records to predict costs and outcomes in stable coronary artery disease.Heart (British Cardiac Society) · 2016Article
- Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER).European heart journal. Quality of care & clinical outcomes · 2016Article
- An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.ClinicoEconomics and outcomes research : CEOR · 2013Article
- Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4.ClinicoEconomics and outcomes research : CEOR · 2013Article
- Cost-effectiveness of a European preventive cardiology programme in primary care: a Markov modelling approach.BMJ open · 2012Article
- Framework and indicator testing protocol for developing and piloting quality indicators for the UK quality and outcomes framework.BMC family practice · 2011Article
- Value for money and the Quality and Outcomes Framework in primary care in the UK NHS.The British journal of general practice : the journal of the Royal College of General Practitioners · 2010Review
- Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004.Circulation. Cardiovascular quality and outcomes · 2010Article
- Subgroups and heterogeneity in cost-effectiveness analysis.PharmacoEconomics · 2008Article
- Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients.PharmacoEconomics · 2008Article
- ACE inhibitors: back to prime time?Heart (British Cardiac Society) · 2007Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) trial has recently reported.
objectiveTo assess the cost effectiveness of perindopril in stable coronary heart disease in the UK.
methodsClinical and resource use data were taken from the EUROPA trial. Costs included drugs and hospitalisations. Health-related quality of life values were taken from published sources. A cost-effectiveness analysis is presented as a function of the risk of a primary event (non-fatal myocardial infarction, cardiac arrest or cardiovascular death) in order to identify people for whom treatment offers greatest value for money.
resultsThe median incremental cost of perindopril for each quality-adjusted life year (QALY) gained across the heterogeneous population of EUROPA was estimated as 9700 pounds(interquartile range 6400-14,200 pounds). Overall, 88% of the EUROPA population had an estimated cost per QALY below 20,000 pounds and 97% below 30,000 pounds. For a threshold value of cost effectiveness of 30,000 pounds per QALY gained, treatment of people representing the 25th, 50th (median) and 75th centiles of the cost effectiveness distribution for perindopril has a probability of 0.999, 0.99 and 0.93 of being cost effective, respectively. Cost effectiveness was strongly related to higher risk of a primary event under standard care.
conclusionsWhether the use of perindopril can be considered cost effective depends on the threshold value of cost effectiveness of healthcare systems. For the large majority of patients included in EUROPA, the incremental cost per QALY gained was lower than the apparent threshold used by the National Institute for Health and Clinical Excellence in the UK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.